References
- European Glaucoma Society. Terminology and guidelines for glaucoma, 2nd ed. Savona, Italy: DOGMA®, Srl; 2003.
- Fechtner RD, Realini T. Fixed combinations of topical glaucoma medications. Curr Opin Ophthalmol 2004;15:132-5
- Toris CB, Camras CB, Yablonski ME. Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes. Ophthalmology 1993;100:1297-304
- Zimmerman TJ, Kaufman HE. Timolol. A beta-adrenergic blocking agent for the treatment of glaucoma. Arch Ophthalmol 1977;95:601-4
- Coakes RL, Brubaker RF. The mechanism of timolol in lowering intraocular pressure in the normal eye. Arch Ophthalmol 1978; 96:2045-8
- Diestelhorst M, Almegard B. Comparison of two fixed combinations of latanoprost and timolol in open-angle glaucoma. Graefe's Arch Clin Exp Ophthalmol 1998;236:577-81
- Higginbotham EJ, Feldman R, Stiles M,. et al. Latanoprost and timolol combination therapy versus monotherapy: one-year randomized trial. Arch Ophthalmol 2002;120:915-22
- Pfeiffer N, European Latanoprost Fixed Combination Study Group. A comparison of the fixed combination of latanoprost and timolol with its individual components. Graefe's Arch Clin Exp Ophthalmol 2002;240:893-9.
- Lazaridis A, Lazaridou M-N. Applied medical statistics. Thessaloniki: Biblioekdotiki; 1999. p. 98-102.
- Ray WA, O’Day DM, Head S,. et al. Statistical analysis for experimental models of ocular disease: continuous response measures. Curr Eye Res 1985;5:585-97
- Hamacher T, Schinzel M, Schölzel-Klatt A,. et al. Short term efficacy and safety in glaucoma patients changed to the latanoprost 0.005% timolol maleate 0.5% fixed combination from monotherapies and adjunctive therapies. Br J Ophthalmol 2004; 88:1295-8
- Konstas AGP, Bányai L, Blask K-D,. et al. Intraocular pressure and safety in glaucoma patients switching to latanoprost/timolol maleate fixed combination from mono- and adjunctive therapies. J Ocul Pharmacol Ther 2004;20:375-82
- Olander K, Zimmerman TJ, Downes N, et al; Xalacom/Latanoprost Study Group. Switching from latanoprost to fixed-combination latanoprost-timolol: a 21-day, randomized, double-masked, active-control study in patients with glaucoma and ocular hypertension. Clin Ther 2004;26: 1619-29.
- Konstas AGP, Boboridis K, Tzetzi D, . et al. Twenty-four-hour control with latanoprost-timolol-fixed combination therapy vs latanoprost therapy. Arch Ophthalmol 2005;123:898-902
- Kass MA, Heuer DK, Higginbotham EJ,. et al. The Ocular Hypertension Treatment Study: a randomized trial determines that ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002; 120:701-13
- Leske MC, Heijl A, Hussein M,. et al. Factors for glaucoma progression and the effect of treatment: the Early Manifest Glaucoma Trial. Arch Ophthalmol 2003;121:48-56